Taiwan-developed drug to be tested on severe COVID-19 cases in U.S.
06/04/2021 02:02 PM
A drug candidate developed by a Taiwanese company for the treatment of COVID-19 will be administered to seriously ill patients in its Phase II clinical trials in the United States, pending authorization by the relevant authorities, according to the developer Golden Biotechnology Corp.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Manufacturing sector's Q2 fixed asset investments up on IC expansion
09/15/2025 07:45 PM - Culture
Miniseries tops Golden Bell nods; Netflix show earns 3 lead actress spots
09/15/2025 07:41 PM - Business
Cathay Financial raises Taiwan's 2025 GDP growth forecast to 4.5%
09/15/2025 07:31 PM - Politics
District court again grants bail to ex-Taipei Mayor Ko Wen-je
09/15/2025 07:27 PM - Business
Taiwan shares close lower as investors take profits
09/15/2025 06:12 PM